Determines when to use 68Ga-DOTATATE PET for diagnosing primary head and neck paragangliomas irrespective of genetic variants. Triggers include suspected head/neck PGL requiring sensitive detection, evaluating for SSTR-positive neuroendocrine tumor, and pre-assessment for 177Lu-DOTATATE therapy in HNPGL.
Installs into .claude/skills of the current project.
Are you the author of Ppgl 68ga Dotatate Pet Indication?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-ppgl-68ga-dotatate-pet-indication)
---
name: ppgl-68ga-dotatate-pet-indication
description: Determines when to use 68Ga-DOTATATE PET for diagnosing primary head and neck paragangliomas irrespective of genetic variants. Triggers include suspected head/neck PGL requiring sensitive detection, evaluating for SSTR-positive neuroendocrine tumor, and pre-assessment for 177Lu-DOTATATE therapy in HNPGL.
---
# 68Ga-DOTATATE PET Indication for Head/Neck PGL
## STEP 1 — Gather Information
Collect clinical suspicion of head/neck PGL (e.g., neck mass, cranial nerve palsies, pulsatile tinnitus), biochemical workup (fractionated metanephrines/catecholamines), anatomic imaging (contrast-enhanced MRI of head and neck ± skull base CT), and prior functional imaging if available (e.g., 123I-MIBG scintigraphy). Genetic testing is not required for indication but may be recorded.
## STEP 2 — Rule In / Rule Out
If head/neck PGL is suspected based on clinical or imaging findings → proceed to 68Ga-DOTATATE PET; otherwise, consider alternative diagnostics and do not order the scan.
## STEP 3 — Classify or Stratify
Interpret 68Ga-DOTATATE PET: SSTR-positive uptake in a head/neck lesion consistent with PGL → classify as SSTR-positive HNPGL; absent or non-specific uptake → classify as SSTR-negative or indeterminate.
## STEP 4 — Decide
For SSTR-positive HNPGL, consider 177Lu-DOTATATE peptide receptor radionuclide therapy if therapeutic intervention is indicated; for SSTR-negative or indeterminate results, rely on anatomic imaging and biopsy (if safe) or alternative functional imaging (e.g., 18F-FDG PET) for further evaluation.
## Clinical Guardrails / Mimics / Pitfalls
68Ga-DOTATATE PET is not covered by Japanese health insurance; physiologic uptake in salivary glands, tonsils, and lymphoid tissue can mimic disease—correlate with anatomic imaging. False negatives may occur in very small tumors (<5 mm) or due to high blood glucose causing brown adipose tissue uptake; advise fasting and warm environment. Do not use as a sole diagnostic test without histologic or biochemical confirmation when feasible.
## Concrete Clinical Example
A 48‑year‑old woman presented with a left carotid body tumor and normal plasma metanephrines. Contrast MRI showed a 1.2 cm flow‑void lesion. 68Ga‑DOTATATE PET/CT demonstrated intense focal uptake in the lesion (SUVmax 12.4), confirming SSTR‑positive HNPGL. She was referred for 177Lu‑DOTATATE therapy after multidisciplinary review.
**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165